CD3E, also known as CD3 epsilon, is a critical component of the T-cell receptor (TCR) complex. It plays a significant role in the immune response by mediating signal transduction necessary for T-cell activation and function. The mouse anti-human CD3E antibody is a monoclonal antibody that specifically targets the CD3 epsilon chain in humans. This antibody is widely used in research and clinical applications to study T-cell biology and to develop therapeutic strategies.
CD3E is a 20 kDa transmembrane protein that belongs to the immunoglobulin superfamily. It is primarily expressed on T cells, natural killer T (NKT) cells, and thymocytes at various stages of differentiation . CD3E forms a part of the TCR complex by associating with other CD3 subunits (CD3 delta, CD3 gamma, and CD3 zeta) and the TCR alpha/beta or gamma/delta chains . This complex is essential for the recognition of antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells.
The primary function of CD3E is to transduce activation signals from the TCR to the intracellular signaling pathways. Upon antigen recognition, the TCR-CD3 complex undergoes conformational changes that lead to the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) present in the cytoplasmic domains of CD3 subunits . This phosphorylation event triggers a cascade of downstream signaling pathways, ultimately resulting in T-cell activation, proliferation, and differentiation.
The mouse anti-human CD3E antibody is a monoclonal antibody derived from Syrian hamster immunized with human T cells . This antibody specifically binds to the CD3 epsilon chain on human T cells, making it a valuable tool for various immunological assays and therapeutic applications.
The mouse anti-human CD3E antibody has significant therapeutic potential in the treatment of various immune-related disorders. For instance, it can be used to deplete T cells in conditions such as autoimmune diseases and organ transplantation . Additionally, it can be employed in adoptive T-cell therapies to enhance the efficacy of T-cell-based immunotherapies for cancer .